Q. Werthner
3 Papers
Q. Werthner is an academic researcher. The author has contributed to research in topics: Medicine & Epidemiology. The author has an hindex of 1, co-authored 2 publications.
Chat about Author
Papers
Model-Based Analysis of SARS-CoV-2 Infections, Hospitalization and Outcome in Germany, the Federal States and Districts
Christiane Dings,Katharina A. M. Götz,Katharina Och,I. Sihinevich,Q. Werthner,Sigrun Smola,Marc Bliem,Felix Mahfoud,Thomas Volk,Sascha Kreuer,Jürgen Rissland,Dominik Selzer,Thorsten Lehr +12 more
TL;DR: An epidemiological SARS-CoV-2 infection model for Germany, with its 16 federal states and 400 districts, that describes infections as well as COVID-19 inpatients, ICU patients with and without mechanical ventilation, recoveries, and fatalities during the first two waves of the pandemic until April 2021 is developed.
Human papillomavirus vaccination of girls in the German model region Saarland: Insurance data-based analysis and identification of starting points for improving vaccination rates
Anna Sternjakob-Marthaler,Barbara Berkó-Göttel,Jürgen Rissland,Jakob Schöpe,E. Taurian,Hanna Müller,Gero Weber,Stefan Lohse,T. Lamberty,Bernd Holleczek,Harry Stoffel,Gunter Hauptmann,Martin Giesen,Christiane Firk,A. Schanzenbach,Flora Brandt,Heike Hohmann,Q. Werthner,Dominik Selzer,Thorsten Lehr,Stefan Wagenpfeil,Sigrun Smola +21 more
TL;DR: It is proposed to restructure U 11 and J1 screening in Germany, with mandatory funding for U11 and organized invitations for HPV vaccination at U11 or J1 for both boys and girls, and provide evidence for a significant association between attendance at the children´s medical check-ups “U11” or “J1” and HPV vaccination.
Exploring Patient Pathways and Care Situations in Men With Erectile Dysfunction in Different PDE-5 Inhibitor Regulatory Settings
Uwe May,Q. Werthner,Harald Weigmann,Cosima Bauer +3 more
TL;DR: This study examines the impact of PDE-5 inhibitor prescription requirements on erectile dysfunction management in men across Germany, Norway, Poland, and Switzerland, highlighting the need for prescription-free approval to improve ED treatment and healthcare engagement.